John Maris Laboratory News Updates
1 - 7 of 7
CHOP Researchers Develop a New Class of CAR-T Cells that Target Previously Untargetable Cancer Drivers
Published on
CHOP researchers have developed a novel cancer therapy that targets proteins inside cancer cells that are essential for tumor growth and survival but have been historically impossible to reach.
Cancer Researchers Receive Grant to Study Indolent Neuroblastoma
Published on
Grant awarded to CHOP and collaborating institutions will fund research into identifying and treating slowly progressive neuroblastoma, which currently lacks treatment options.
CHOP Cancer Researchers Win 2021 AACR Team Science Award
Published on
The award was presented to the St. Baldrick’s Foundation-Stand Up 2 Cancer Pediatric Cancer Dream Team, co-led by CHOP, at the annual AACR conference.
Dr. John Maris Receives QED Award to Develop Novel Treatment for Neuroblastoma
Published on
A CHOP research leader received an award from the University City Science Center to help develop a new T-cell based treatment for a childhood cancer.
CHOP Scientists Identify Gene Variants that Increase Neuroblastoma Risk
Published on
By identifying common gene variants that raise the risk of an aggressive form of the childhood cancer neuroblastoma, researchers may assist diagnostic efforts.
Change in a Single DNA Base Drives a Childhood Cancer
Published on
CHOP pediatric oncology researchers have pinpointed a crucial change in a single DNA “letter” that predisposes children to an aggressive form of neuroblastoma.
Pinpointing Mutations in a Relapsed Cancer May Lead to Better Treatments
Published on
CHOP neuroblastoma researchers have detailed how cancer-driving mutations evolve during chemotherapy, and they aim to exploit this knowledge to design better treatments for children.